Skip to main content
04/07/2023

Barcelona has hosted the 6th World Parkinson's Congress

Parkinson-congres-Barcelona
parkinson-congres-grup-VHIR

04/07/2023

Dr. Miquel Vila, head of the Neurodegenerative Diseases research group at VHIR, was the co-chair of the local organising committee. And Dr. Ariadna Laguna, principal investigator of the same group, was a scientific ambassador.

From 3 to 7 July, Barcelona hosted the 6th World Parkinson's Congress. This is the first time this congress has been held in Spain and was visited by more than 5,000 people from all over the world. The attendees were people with some kind of relationship with the disease: scientists, neurologists, nurses, specialists in movement disorders, physiotherapists and occupational therapists, phoniatricians, speech therapists and social workers, along with people with Parkinson's, their families and caregivers.

During the event, conferences and talks were given on advances in research and clinical practice, such as updates on the status of cures and new models of health care for Parkinson's patients. On the part of Vall d'Hebron, apart from presenting more than a dozen posters, the most outstanding interventions were given by researchers from the Neurodegenerative Diseases research group:

  • The role of syncline and Lewy bodies, by Dr. Miquel Vila, head of the research group and co-chair of the local organising committee of the Congress. He also participated in a round table
  • The science behind sex differences, by Dr. Ariadna Laguna, principal investigator and scientific ambassador of the Congress.
  • Clinical fluctuations and dyskinesias, by Dr. Oriol de Fàbregas, neurologist in charge of the Movement Disorders Unit of the Neurology Service of the Vall d'Hebron University Hospital and principal investigator.
  • Modelling human brain-wide brain pigmentation induces Parkinson-like pathology and transcriptomic alterations in vivo, by Dr. Nuria Peñuelas, researcher.

 

 

Related news

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Related professionals

Miquel Vila Bover

Miquel Vila Bover

Head of group
Neurodegenerative Diseases
Read more
Ariadna Laguna Tuset

Ariadna Laguna Tuset

Main researcher
Neurodegenerative Diseases
Read more
Oriol de Fabregues-Boixar Nebot

Oriol de Fabregues-Boixar Nebot

Main researcher
Neurodegenerative Diseases
Read more
Javier Hoyo Pérez

Javier Hoyo Pérez

Administration and Management
Neurodegenerative Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.